

# CITATION REPORT

List of articles citing

**Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin**

**DOI: 10.1111/j.1365-2036.2006.02879.x**

**Alimentary Pharmacology and Therapeutics, 2006, 23, 1117-2**

**Source:** <https://exaly.com/paper-pdf/40425827/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
184	The role of antibiotic and probiotic therapies in current and future management of inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , <b>2006</b> , 8, 486-98	5	37
183	Medical management of Crohn's disease. <b>2007</b> , 20, 269-81		9
182	Mild-to-moderate active luminal Crohn's disease. <b>2007</b> , 76, 92-8		3
181	Drug safety in Crohn's disease therapy. <b>2007</b> , 76, 161-8		15
180	Inflammatory bowel diseases in the elderly. <b>2007</b> , 23, 809-21, vi		9
179	Current medical therapy for chronic inflammatory bowel diseases. <b>2007</b> , 87, 697-725		15
178	Bacteria, bugs, and BID rifaximin for Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2007</b> , 13, 800-801	4.5	
177	Adherent-invasive Escherichia coli isolated from Crohn's disease patients induce granulomas in vitro. <b>2007</b> , 9, 1252-61		97
176	Microbial host interactions in IBD: implications for pathogenesis and therapy. <i>Current Gastroenterology Reports</i> , <b>2007</b> , 9, 497-507	5	87
175	Mild to moderate Crohn's disease: an evidence-based treatment algorithm. <b>2008</b> , 68, 2419-25		6
174	Rifaximin for the treatment of newly diagnosed Crohn's disease: a case series. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2158-60	0.7	12
173	Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters. <b>2008</b> , 52, 1121-6		38
172	Indomethacin may reduce the incidence and severity of acute pancreatitis after ERCP. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 244	0.7	5
171	The endoscopic appearance of focal gastric hemosiderosis as a brown macular patch resembling that of cutaneous iron deposition in hemochromatosis. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 246-8	0.7	6
170	Metronidazole and vancomycin: equivalence of initial efficacy in CDAD. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2147; author reply 2147	0.7	
169	Usefulness of prophylactic gastrectomy in a novel large hereditary diffuse gastric cancer (HDGC) family. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2160-1	0.7	22
168	Prevalence of CARD15/NOD2 mutations in the Sicilian population. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 248-9	0.7	2

167	Treatment of recurrent Crohn's uveitis with infliximab. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2150-1	0.7	22
166	What role do antibiotics have in the treatment of IBD?. <b>2008</b> , 5, 670-1		12
165	Success of antireflux surgery and postoperative use of antireflux medications. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2144-5; author reply 2145	0.7	
164	Perfusion CT to Predict the Development of Necrosis in Severe Acute Pancreatitis: More Studies Are Needed. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2146-2147	0.7	1
163	Response to Letter by von Kalckreuth et al.. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2148-2148	0.7	
162	Unmasking autoimmune hepatitis under immunomodulatory treatment of multiple sclerosis--not only beta interferon. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2147-8; author reply 2148	0.7	9
161	Endoscopic application of ankaferd blood stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: a case report. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2156-8	0.7	82
160	"Ecologic niche" therapy for Crohn's disease with adjunctive rifaximin antibiotic treatment followed by Flora-Q probiotic maintenance therapy. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 251-2	0.7	6
159	PEG feeding and dementia--results need to be interpreted with caution. Is this the time for a randomized controlled study?. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2143; author reply 2143-4	0.7	3
158	Response to the Letter by Leeds et al.. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2143-2144	0.7	1
157	Pancreatic exocrine insufficiency: a rare cause of nonalcoholic steatohepatitis. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 245-6	0.7	11
156	Response to Burman. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2147-2147	0.7	8
155	Long-term follow-up of atypical progressive focal nodular hyperplasia increasing in size and number implicates its pathogenesis. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2153-5	0.7	6
154	Response to Dr. Rashid and Colleagues. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 243-244	0.7	
153	Observation of deworming process in intestinal <i>Diphyllobothrium latum</i> parasitism by gastrografin injection into jejunum through double-balloon enteroscope. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2149-50	0.7	4
152	Feasibility of polyethylene glycol (PEG) 3350 (Miralax) for colon preparation prior to lower endoscopic examination in healthy adults; experience in a community clinic setting. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2163-4	0.7	10
151	Oral butyrate in treatment of congenital chloride diarrhea. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 252-4	0.7	22
150	Consequences of detecting small bowel metastasis of malignant melanoma by capsule endoscopy. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 244-5	0.7	5

149	Response to Comments About [Long-Term Outcomes After Laparoscopic Antireflux Surgery] <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2145-2145	0.7	
148	Intercellular invasion of <i>Helicobacter pylori</i> and delayed healing of a gastric ulcer. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 249-50	0.7	1
147	Inflammatory bowel disease in the South Asian population of Northwest England. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 242-3; author reply 243-4	0.7	8
146	The influential factors of left atrial volume. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 241; author reply 241	0.7	
145	Diabetes as a risk factor for infections in cirrhosis. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 248	0.7	9
144	Erythropoietin does not increase the frequency of thromboembolic events or hepatocellular carcinoma in hepatitis C patients treated with combination antiviral therapy. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2161-2	0.7	1
143	The location of intestinal metaplasia within a columnar-lined esophagus. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 250-1	0.7	
142	Sorafenib-induced liver failure. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2162-3	0.7	31
141	Are prophylactic antibiotics really ineffective in reducing the risk of pancreatic necrosis?. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2145-6; author reply 2146-7	0.7	2
140	Echinococcus in a U.S. Marine after deployment to Afghanistan. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2151-3	0.7	5
139	Response to Dr. Ze-Zhou Song. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 241-241	0.7	
138	Rapidly progressive neurological complication of Crohn's disease. <i>American Journal of Gastroenterology</i> , <b>2008</b> , 103, 2164-6	0.7	
137	Replication of Colonic Crohn's Disease Mucosal <i>Escherichia coli</i> Isolates within Macrophages and Their Susceptibility to Antibiotics. <b>2008</b> , 52, 427-34		74
136	[Clinical practice guideline on diagnosis and treatment of Crohn's disease]. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2008</b> , 46, 1094-146	1.6	96
135	Specific considerations in the treatment of pediatric inflammatory bowel disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2008</b> , 2, 105-24	4.2	9
134	Pathophysiology of Inflammatory Bowel Diseases. <b>2008</b> , 341-373		0
133	Molecular pathogenesis of inflammatory bowel disease: relevance for novel therapies. <b>2008</b> , 5, 609-626		2
132	Treatment of inflammatory bowel disease: a review of medical therapy. <i>World Journal of Gastroenterology</i> , <b>2008</b> , 14, 354-77	5.6	163

131	[Diarrhea, from the gastroenterologist's point of view]. <b>2009</b> , 150, 1655-61		3
130	The role of rifaximin in the treatment and chemoprophylaxis of travelers' diarrhea. <b>2009</b> , 5, 841-8		8
129	<i>Campylobacter concisus</i> : a new character in the Crohn's disease story?. <b>2009</b> , 47, 1614-5		5
128	A randomized, double-blind, placebo-controlled trial of rifaximin, a nonabsorbable antibiotic, in the treatment of tropical enteropathy. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 2326-33	0.7	67
127	Use and safety of rifaximin in children with inflammatory bowel disease. <b>2009</b> , 49, 400-4		24
126	A new animal model of postsurgical bowel inflammation and fibrosis: the effect of commensal microflora. <i>Gut</i> , <b>2009</b> , 58, 1104-12	19.2	35
125	Debugging the intestinal microbiota in IBD. <b>2009</b> , 33 Suppl 3, S131-6		2
124	A lump of coal for perianal fistulae?. <i>Inflammatory Bowel Diseases</i> , <b>2009</b> , 15, 1276-7	4.5	
123	Optimizing conventional therapies for inflammatory bowel disease. <i>Current Gastroenterology Reports</i> , <b>2009</b> , 11, 496-503	5	10
122	Rifaximin pharmacology and clinical implications. <b>2009</b> , 5, 675-82		35
121	Targeting the human microbiome with antibiotics, probiotics, and prebiotics: gastroenterology enters the metagenomics era. <i>Gastroenterology</i> , <b>2009</b> , 136, 2015-31	13.3	351
120	Intestinal bacteria and inflammatory bowel disease. <b>2009</b> , 46, 25-54		67
119	Treatment of even mild to moderate Crohn's disease is a long-term challenge due to its remitting and relapsing course. <b>2009</b> , 25, 10-12		
118	Management of Crohn's disease in adults. <i>American Journal of Gastroenterology</i> , <b>2009</b> , 104, 465-83; quiz 464, 484	0.7	691
117	Antibiotics and probiotics in inflammatory bowel disease: why, when, and how. <b>2009</b> , 25, 329-33		31
116	Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. <b>2010</b> , 26, 17-25		115
115	[New therapeutic approaches to special diseases of the small intestine]. <b>2010</b> , 51, 730-6		
114	Adjunctive antibiotic therapy with rifaximin may help reduce Crohn's disease activity. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 1079-84	4	34

113	Rifaximin and Crohn's disease: a new solution to an old problem?. <i>Digestive Diseases and Sciences</i> , <b>2010</b> , 55, 877-9	4	8
112	Meta-analysis: targeting the intestinal microbiota in prophylaxis for post-operative Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2010</b> , 31, 802-9	6.1	62
111	Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. <b>2010</b> , 50, 473-80		84
110	Rifaximin modulates the colonic microbiota of patients with Crohn's disease: an in vitro approach using a continuous culture colonic model system. <b>2010</b> , 65, 2556-65		120
109	What options do we have for induction therapy for Crohn's disease?. <i>Digestive Diseases</i> , <b>2010</b> , 28, 543-7	3.2	5
108	Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections. <b>2010</b> , 8, 747-60		10
107	Emerging drugs to treat Crohn's disease. <b>2010</b> , 15, 309-22		1
106	Biologic properties and clinical uses of rifaximin. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 293-302	4	34
105	Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106, 661-73	0.7	390
104	Combined azithromycin and metronidazole therapy is effective in inducing remission in pediatric Crohn's disease. <i>Journal of Crohns and Colitis</i> , <b>2011</b> , 5, 222-6	1.5	32
103	The role of bacteria and pattern-recognition receptors in Crohn's disease. <b>2011</b> , 8, 152-68		120
102	An evidence-based systematic review on medical therapies for inflammatory bowel disease. <i>American Journal of Gastroenterology</i> , <b>2011</b> , 106 Suppl 1, S2-25; quiz S26	0.7	205
101	Medical management of Crohn's disease. <i>Expert Opinion on Pharmacotherapy</i> , <b>2011</b> , 12, 2505-25	4	15
100	Rosacea in Crohn's Disease: Effect of Rifaximin. <b>2011</b> , 45, 295-6		5
99	A meta-analysis of randomized controlled trials comparing antibacterial therapy with placebo in Crohn's disease. <b>2011</b> , 13, 617-26		10
98	Inhibition of NF- $\kappa$ B by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells. <b>2011</b> , 668, 317-24		74
97	Inflammatory Bowel Disease. <b>2011</b> ,		2
96	Optimization of conventional therapy in patients with IBD. <b>2011</b> , 8, 646-56		48

95	Variation in Antibiotic Use for Children Hospitalized With Inflammatory Bowel Disease Exacerbation: A Multicenter Validation Study. <b>2012</b> , 1, 306-13		11
94	Meta-analysis of broad-spectrum antibiotic therapy in patients with active inflammatory bowel disease. <b>2012</b> , 4, 1051-1056		81
93	Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn's disease. <i>Gastroenterology</i> , <b>2012</b> , 142, 473-481.e4	13.3	133
92	Manipulation of Intestinal Flora as a Way to Treat Crohn's Disease: The Role of Probiotics, Prebiotics and Antibiotics. <b>2012</b> ,		
91	The role of anti(myco)bacterial interventions in the management of IBD: is there evidence at all?. <i>Digestive Diseases</i> , <b>2012</b> , 30, 358-67	3.2	12
90	Microbial translocation across the GI tract. <b>2012</b> , 30, 149-73		294
89	Innate immune dysfunction in inflammatory bowel disease. <b>2012</b> , 271, 421-8		102
88	Multidrug resistance is common in Escherichia coli associated with ileal Crohn's disease. <i>Inflammatory Bowel Diseases</i> , <b>2013</b> , 19, 141-50	4.5	53
87	Recent developments in the treatment of inflammatory bowel disease. <i>Journal of Digestive Diseases</i> , <b>2013</b> , 14, 282-7	3.3	25
86	Antibiotics and inflammatory bowel diseases. <i>Digestive Diseases</i> , <b>2013</b> , 31, 379-84	3.2	19
85	Rifaximin resistance in Escherichia coli associated with inflammatory bowel disease correlates with prior rifaximin use, mutations in rpoB, and activity of Phe-Arg-β-naphthylamide-inhibitable efflux pumps. <b>2013</b> , 57, 811-7		47
84	The role of antimicrobials in Crohn's disease. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2013</b> , 7, 281-8	4.2	12
83	Comparing medical treatments for Crohn's disease. <i>Journal of Comparative Effectiveness Research</i> , <b>2013</b> , 2, 135-49	2.1	2
82	Preventing recurrent acute diverticulitis with pharmacological therapies. <i>Therapeutic Advances in Chronic Disease</i> , <b>2013</b> , 4, 277-86	4.9	8
81	Rationale for the use of rifaximin in inflammatory bowel diseases based on clinical trial results. <i>Clinical Investigation</i> , <b>2013</b> , 3, 1187-1193		
80	Medical management of Crohn's disease. <b>2013</b> , 104-122		
79	Probiotics and antibiotics in IBD. <i>Digestive Diseases</i> , <b>2014</b> , 32 Suppl 1, 10-7	3.2	33
78	[Updated German clinical practice guideline on "Diagnosis and treatment of Crohn's disease" 2014]. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2014</b> , 52, 1431-84	1.6	106

77	Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management. <i>Postgraduate Medicine</i> , <b>2014</b> , 126, 7-19	3.7	192
76	Exploring & exploiting our 'other self' - does the microbiota hold the key to the future therapy in Crohn's?. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2014</b> , 28, 399-409	2.5	10
75	New targets for mucosal healing and therapy in inflammatory bowel diseases. <i>Mucosal Immunology</i> , <b>2014</b> , 7, 6-19	9.2	213
74	Classical and recent advances in the treatment of inflammatory bowel diseases. <i>Brazilian Journal of Medical and Biological Research</i> , <b>2015</b> , 48, 96-107	2.8	58
73	Medical Therapy for Crohn's Disease: The Present. <b>2015</b> , 35-48		
72	Targeting the Microbiome in Inflammatory Bowel Disease: Critical Evaluation of Current Concepts and Moving to New Horizons. <i>Digestive Diseases</i> , <b>2015</b> , 33 Suppl 1, 105-112	3.2	22
71	Use of antibiotics in patients with Crohn's disease: a systematic review and meta-analysis. <i>Journal of Digestive Diseases</i> , <b>2015</b> , 16, 58-66	3.3	44
70	Rifaximin for the treatment of diarrhoea-predominant irritable bowel syndrome. <i>Expert Opinion on Pharmacotherapy</i> , <b>2015</b> , 16, 607-15	4	12
69	The involvement of gut microbiota in inflammatory bowel disease pathogenesis: potential for therapy. <i>Pharmacology &amp; Therapeutics</i> , <b>2015</b> , 149, 191-212	13.9	110
68	Controlled delivery of a new broad spectrum antibacterial agent against colitis: In vitro and in vivo performance. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , <b>2015</b> , 96, 152-61	5.7	10
67	Therapeutic Effects and Mechanisms of Action of Rifaximin in Gastrointestinal Diseases. <i>Mayo Clinic Proceedings</i> , <b>2015</b> , 90, 1116-24	6.4	23
66	Crohn's Disease. <b>2015</b> , 1613-1635		
65	Crohn's Disease. <b>2015</b> ,		1
64	Recent advances in understanding and managing Crohn's disease. <i>F1000Research</i> , <b>2016</b> , 5, 2896	3.6	12
63	Modulating Composition and Metabolic Activity of the Gut Microbiota in IBD Patients. <i>International Journal of Molecular Sciences</i> , <b>2016</b> , 17,	6.3	43
62	The Role of Antibiotics in Gut Microbiota Modulation: The Eubiotic Effects of Rifaximin. <i>Digestive Diseases</i> , <b>2016</b> , 34, 269-78	3.2	72
61	The intestinal microbiome, barrier function, and immune system in inflammatory bowel disease: a tripartite pathophysiological circuit with implications for new therapeutic directions. <i>Therapeutic Advances in Gastroenterology</i> , <b>2016</b> , 9, 606-25	4.7	104
60	Inflicting Confusion. <i>AORN Journal</i> , <b>2016</b> , 104, 90-54	0.6	



59	Endoscopic Delivery of Fecal Biotherapy in Inflammatory Bowel Disease. <i>Gastrointestinal Endoscopy Clinics of North America</i> , <b>2016</b> , 26, 707-17	3.3	5
58	Pregnane X Receptor Activation Attenuates Inflammation-Associated Intestinal Epithelial Barrier Dysfunction by Inhibiting Cytokine-Induced Myosin Light-Chain Kinase Expression and c-Jun N-Terminal Kinase 1/2 Activation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , <b>2016</b> , 359, 91-101	4.7	39
57	Rifamycins, Alone and in Combination. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2016</b> , 6,	5.4	52
56	Rifaximin preserves intestinal microbiota balance in patients undergoing allogeneic stem cell transplantation. <i>Bone Marrow Transplantation</i> , <b>2016</b> , 51, 1087-92	4.4	71
55	Practical Considerations and the Intestinal Microbiome in Disease: Antibiotics for IBD Therapy. <i>Digestive Diseases</i> , <b>2016</b> , 34, 112-21	3.2	6
54	Intestinal microbiota, fecal microbiota transplantation, and inflammatory bowel disease. <i>Gut Microbes</i> , <b>2017</b> , 8, 238-252	8.8	145
53	Rifaximin and diverticular disease: Position paper of the Italian Society of Gastroenterology (SIGE). <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 595-603	3.3	22
52	Antibiotics in IBD: Still a Role in the Biological Era?. <i>Inflammatory Bowel Diseases</i> , <b>2018</b> , 24, 1676-1688	4.5	40
51	Update on Bile Acid Malabsorption: Finally Ready for Prime Time?. <i>Current Gastroenterology Reports</i> , <b>2018</b> , 20, 10	5	21
50	Review article: the gut microbiome in inflammatory bowel disease-avenues for microbial management. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 47, 26-42	6.1	107
49	The intriguing role of Rifaximin in gut barrier chronic inflammation and in the treatment of Crohn's disease. <i>Expert Opinion on Investigational Drugs</i> , <b>2018</b> , 27, 543-551	5.9	9
48	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <i>Gastroenterology</i> , <b>2019</b> , 157, 320-348	13.3	25
47	Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn's Disease. <i>Journal of the Canadian Association of Gastroenterology</i> , <b>2019</b> , 2, e35-e63	0.5	8
46	Antibiotics for induction and maintenance of remission in Crohn's disease. <i>The Cochrane Library</i> , <b>2019</b> , 2, CD012730	5.2	12
45	ATCC 8483 monotherapy is superior to traditional fecal transplant and multi-strain bacteriotherapy in a murine colitis model. <i>Gut Microbes</i> , <b>2019</b> , 10, 504-520	8.8	30
44	Antibiotics in inflammatory bowel diseases: do we know what we're doing?. <i>Translational Pediatrics</i> , <b>2019</b> , 8, 42-55	4.2	16
43	Systematic review: outcomes and adverse events from randomised trials in Crohn's disease. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 978-996	6.1	8
42	Emerging roles of bile acids in mucosal immunity and inflammation. <i>Mucosal Immunology</i> , <b>2019</b> , 12, 851-861	8.6	89

41	Nuclear Receptors in the Pathogenesis and Management of Inflammatory Bowel Disease. <i>Mediators of Inflammation</i> , <b>2019</b> , 2019, 2624941	4.3	13
40	Azithromycin and metronidazole versus metronidazole-based therapy for the induction of remission in mild to moderate paediatric Crohn's disease : a randomised controlled trial. <i>Gut</i> , <b>2019</b> , 68, 239-247	19.2	20
39	Antibiotics and probiotics in inflammatory bowel disease: when to use them?. <i>Frontline Gastroenterology</i> , <b>2020</b> , 11, 62-69	2.6	16
38	Double-blind, randomised, placebo-controlled crossover trial to evaluate the clinical efficacy of rifaximin in patients with moderate to severe active Crohn's disease. <i>GastroHep</i> , <b>2020</b> , 2, 185-192	1	1
37	Nuclear receptor phosphorylation in xenobiotic signal transduction. <i>Journal of Biological Chemistry</i> , <b>2020</b> , 295, 15210-15225	5.4	17
36	Immunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIV. <i>Current HIV/AIDS Reports</i> , <b>2020</b> , 17, 394-404	5.9	2
35	Microbial-Based and Microbial-Targeted Therapies for Inflammatory Bowel Diseases. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 757-788	4	52
34	Sustainable Microbiome: a symphony orchestrated by synthetic phages. <i>Microbial Biotechnology</i> , <b>2021</b> , 14, 45-50	6.3	1
33	Gut Microbiome and Gastrointestinal Disorders. <i>The Microbiomes of Humans, Animals, Plants, and the Environment</i> , <b>2021</b> , 41-91		
32	Modulation of the Gut Microbiota-farnesoid X Receptor Axis Improves Deoxycholic Acid-induced Intestinal Inflammation in Mice. <i>Journal of Crohns and Colitis</i> , <b>2021</b> , 15, 1197-1210	1.5	7
31	Role of the global gut microbial community in the development of colitis-associated cancer in a murine model. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 135, 111206	7.5	4
30	Recent Advances in Diagnosis and Management of Crohn's Disease.		
29	Rifaximin: unique selective antibiotic for the treatment of gastrointestinal diseases. <i>Meditinskiy Sovet</i> , <b>2021</b> , 167-174	0.4	
28	Antibiotics in pediatric inflammatory bowel diseases: a systematic review. <i>Expert Review of Gastroenterology and Hepatology</i> , <b>2021</b> , 15, 891-908	4.2	1
27	Fecal Microbiome Transplantation: An Offhand Recipe for Microbiome Therapeutics. <b>2022</b> , 246-246		
26	Prebiotics, Probiotics, Antibiotics, and Nutritional Therapies in IBD. <b>2011</b> , 123-150		2
25	Rifamycins. <b>2010</b> , 403-417		1
24	Crohn's Disease. <b>2010</b> , 1941-1973.e9		4

23	Dynamic colonization of microbes and their functions after fecal microbiota transplantation for inflammatory bowel disease.		0
22	Effects of Vitamin D3 on Intestinal Flora in a Mouse Model of Inflammatory Bowel Disease Treated with Rifaximin. <i>Medical Science Monitor</i> , <b>2020</b> , 26, e925068	3.2	1
21	Current and emerging drugs for the treatment of inflammatory bowel disease. <i>Drug Design, Development and Therapy</i> , <b>2011</b> , 5, 185-210	4.4	173
20	Targeting intestinal microflora in inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2006</b> , 12, 7225-6	5.6	2
19	Rifaximin in the treatment of inflammatory bowel disease. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 4643-6	5.6	34
18	Microbial manipulation as primary therapy for Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 1513-6	5.6	4
17	Role of Salmonella enterica exposure in Chilean Crohn's disease patients. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 5855-62	5.6	8
16	Use of antibiotics in the treatment of Crohn's disease. <i>World Journal of Gastroenterology</i> , <b>2013</b> , 19, 648-536	5.6	22
15	Effect of rifaximin on gut microbiota composition in advanced liver disease and its complications. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 12322-33	5.6	47
14	Use of rifaximin in gastrointestinal and liver diseases. <i>World Journal of Gastroenterology</i> , <b>2016</b> , 22, 6638-5.6	5.6	28
13	Rifaximin for the Treatment of Newly Diagnosed Crohn's Disease: A Case Series. <i>American Journal of Gastroenterology</i> , <b>2008</b> , ???-???	0.7	
12	Standard Therapeutic Approach. <b>2010</b> , 109-121		
11	The Role of the Pathologist in the Management of Patients with Crohn's Disease. <b>2010</b> , 31-41		
10	Role of antibiotics and probiotics in Crohn's disease. 159-161		
9	State-of-the-Art Lecture: Future therapies in inflammatory bowel diseases. 232-242		
8	Crohn's disease. <i>Clinical Evidence</i> , <b>2007</b> , 2007,		
7	Rifaximin: recent advances in gastroenterology and hepatology. <i>Gastroenterology and Hepatology</i> , <b>2007</b> , 3, 474-83	0.7	2
6	Crohn's disease. <i>Clinical Evidence</i> , <b>2011</b> , 2011,		1

5	Influence of Environmental Factors in the Development and Outcomes of Inflammatory Bowel Disease. <i>Gastroenterology and Hepatology</i> , <b>2019</b> , 15, 72-82	0.7	14
4	Contribution of the Gut Microbiota to Intestinal Fibrosis in Crohn's Disease.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 826240	4.9	0
3	Role of Bile Acids and Nuclear Receptors in Acupuncture in Improving Crohn's Disease. <i>Evidence-based Complementary and Alternative Medicine</i> , <b>2022</b> , 2022, 1-11	2.3	
2	New insights into the interplay between intestinal flora and bile acids in inflammatory bowel disease. 10, 10823-10839		0
1	Microbial Modulation in Inflammatory Bowel Diseases. <b>2022</b> , 22,		0